Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BICYCLE THERAPEUTICS PLC
Report date July 13, 2021 · Filed July 20, 2021 · Amendment
Section 16 reporting ended · disclosed 2021-07-20. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectBy SV Life Sciences Fund V, L.P. | 1,831,671 |
Last balance in matching sequence
After 2021-07-14 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2021-07-13 · Sale · Disposed 588 · Balance 1,875,049 F1: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. F2: These shares were sold by SVLS V LP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein. Row 2 · 2021-07-14 · Sale · Disposed 43,378 · Balance 1,831,671 F1: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. F2: These shares were sold by SVLS V LP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy SV Life Sciences Fund V Strategic Partners, L.P. | 38,708 |
Last balance in matching sequence
After 2021-07-14 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 3 · 2021-07-13 · Sale · Disposed 12 · Balance 39,625 F3: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. F4: These shares were sold by SVLS V SPP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein. Row 4 · 2021-07-14 · Sale · Disposed 917 · Balance 38,708 F3: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. F4: These shares were sold by SVLS V SPP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.
F2: These shares were sold by SVLS V LP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein.
F3: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.
F4: These shares were sold by SVLS V SPP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 14, 2021 Filed Jul 15, 2021 19:03 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 917 | $34.01 | $31,184.97 |
DisclosureSEC source: 0000899243-21-028546 · doc4.xml · nonDerivative · entry 4 BINGHAM KATE · CIK 0001185040 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V Strategic Partners, L.P. Disclosed balance after: 38,708 F3 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. F4 · ownership.nature: These shares were sold by SVLS V SPP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein. Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 19:03 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 43,378 | $34.01 | $1,475,181.67 |
DisclosureSEC source: 0000899243-21-028546 · doc4.xml · nonDerivative · entry 2 BINGHAM KATE · CIK 0001185040 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V, L.P. Disclosed balance after: 1,831,671 F1 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. F2 · ownership.nature: These shares were sold by SVLS V LP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein. Read SEC document |
| July 14, 2021 Filed Jul 20, 2021 16:17 UTC Amendment | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 917 | $34.01 | $31,184.97 |
DisclosureSEC source: 0000899243-21-028984 · doc4a.xml · nonDerivative · entry 4 BINGHAM KATE · CIK 0001185040 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V Strategic Partners, L.P. Disclosed balance after: 38,708 F3 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. F4 · ownership.nature: These shares were sold by SVLS V SPP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein. Read SEC document |
| July 14, 2021 Filed Jul 20, 2021 16:17 UTC Amendment | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 43,378 | $34.01 | $1,475,181.67 |
DisclosureSEC source: 0000899243-21-028984 · doc4a.xml · nonDerivative · entry 2 BINGHAM KATE · CIK 0001185040 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V, L.P. Disclosed balance after: 1,831,671 F1 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. F2 · ownership.nature: These shares were sold by SVLS V LP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein. Read SEC document |
| July 13, 2021 Filed Jul 15, 2021 19:03 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 12 | $33.50 | $402.00 |
DisclosureSEC source: 0000899243-21-028546 · doc4.xml · nonDerivative · entry 3 BINGHAM KATE · CIK 0001185040 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V Strategic Partners, L.P. Disclosed balance after: 39,625 F3 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. F4 · ownership.nature: These shares were sold by SVLS V SPP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein. Read SEC document |
| July 13, 2021 Filed Jul 15, 2021 19:03 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 588 | $33.50 | $19,698.00 |
DisclosureSEC source: 0000899243-21-028546 · doc4.xml · nonDerivative · entry 1 BINGHAM KATE · CIK 0001185040 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V, L.P. Disclosed balance after: 1,875,049 F1 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. F2 · ownership.nature: These shares were sold by SVLS V LP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein. Read SEC document |
| July 13, 2021 Filed Jul 20, 2021 16:17 UTC Amendment | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 12 | $33.50 | $402.00 |
DisclosureSEC source: 0000899243-21-028984 · doc4a.xml · nonDerivative · entry 3 BINGHAM KATE · CIK 0001185040 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V Strategic Partners, L.P. Disclosed balance after: 39,625 F3 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. F4 · ownership.nature: These shares were sold by SVLS V SPP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein. Read SEC document |
| July 13, 2021 Filed Jul 20, 2021 16:17 UTC Amendment | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 588 | $33.50 | $19,698.00 |
DisclosureSEC source: 0000899243-21-028984 · doc4a.xml · nonDerivative · entry 1 BINGHAM KATE · CIK 0001185040 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V, L.P. Disclosed balance after: 1,875,049 F1 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. F2 · ownership.nature: These shares were sold by SVLS V LP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 17:25 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $17.95 | $0.00 |
DisclosureSEC source: 0001209191-21-001321 · doc4.xml · derivative · entry 1 BINGHAM KATE · CIK 0001185040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Ordinary Shares · 19,000 shares Expires 2031-01-04 Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 16:51 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $9.82 | $0.00 |
DisclosureSEC source: 0001209191-20-001917 · doc4.xml · derivative · entry 1 BINGHAM KATE · CIK 0001185040 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Ordinary Shares · 16,000 shares Expires 2030-01-02 Read SEC document |
| May 28, 2019 Filed May 30, 2019 21:26 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | ConversionSeries B1 Preferred Shares · Derivative | 13,169 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-032915 · a4.xml · derivative · entry 10 BINGHAM KATE · CIK 0001185040 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V Strategic Partners. L.P. Disclosed balance after: 0 Underlying: Ordinary Shares · 13,169 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F3 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein Read SEC document |
| May 28, 2019 Filed May 30, 2019 21:26 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | ConversionSeries A Preferred Shares · Derivative | 18,485 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-032915 · a4.xml · derivative · entry 9 BINGHAM KATE · CIK 0001185040 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V Strategic Partners. L.P. Disclosed balance after: 0 Underlying: Ordinary Shares · 18,485 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F3 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein Read SEC document |
| May 28, 2019 Filed May 30, 2019 21:26 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | ConversionSeries B1 Preferred Shares · Derivative | 623,196 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-032915 · a4.xml · derivative · entry 8 BINGHAM KATE · CIK 0001185040 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V, L.P. Disclosed balance after: 0 Underlying: Ordinary Shares · 623,196 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document |
| May 28, 2019 Filed May 30, 2019 21:26 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | ConversionSeries A Preferred Shares · Derivative | 874,709 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-032915 · a4.xml · derivative · entry 7 BINGHAM KATE · CIK 0001185040 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V, L.P. Disclosed balance after: 0 Underlying: Ordinary Shares · 874,709 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document |
| May 28, 2019 Filed May 30, 2019 21:26 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | PurchaseOrdinary Shares | 7,983 | $14.00 | $111,762.00 |
DisclosureSEC source: 0001104659-19-032915 · a4.xml · nonDerivative · entry 6 BINGHAM KATE · CIK 0001185040 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V Strategic Partners. L.P. Disclosed balance after: 39,637 F3 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein Read SEC document |
| May 28, 2019 Filed May 30, 2019 21:26 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | PurchaseOrdinary Shares | 377,732 | $14.00 | $5,288,248.00 |
DisclosureSEC source: 0001104659-19-032915 · a4.xml · nonDerivative · entry 5 BINGHAM KATE · CIK 0001185040 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V, L.P. Disclosed balance after: 1,875,637 F2 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document |
| May 28, 2019 Filed May 30, 2019 21:26 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | ConversionOrdinary Shares | 13,169 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-032915 · a4.xml · nonDerivative · entry 4 BINGHAM KATE · CIK 0001185040 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V Strategic Partners. L.P. Disclosed balance after: 31,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F3 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein Read SEC document |
| May 28, 2019 Filed May 30, 2019 21:26 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | ConversionOrdinary Shares | 18,485 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-032915 · a4.xml · nonDerivative · entry 3 BINGHAM KATE · CIK 0001185040 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V Strategic Partners. L.P. Disclosed balance after: 18,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F3 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein Read SEC document |
| May 28, 2019 Filed May 30, 2019 21:26 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | ConversionOrdinary Shares | 623,196 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-032915 · a4.xml · nonDerivative · entry 2 BINGHAM KATE · CIK 0001185040 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V, L.P. Disclosed balance after: 1,497,905 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document |
| May 28, 2019 Filed May 30, 2019 21:26 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | ConversionOrdinary Shares | 874,709 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-032915 · a4.xml · nonDerivative · entry 1 BINGHAM KATE · CIK 0001185040 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By SV Life Sciences Fund V, L.P. Disclosed balance after: 874,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.